PBGENE-HBV
Gene Therapy Target: cccDNA, integrated HBV DNA
Precision Biosciences
Most recent annual filing: 2026-03-12
- PBGENE-HBV readoutyear-end 2026PBGENE-HBV readout, year-end 2026, major
- PBGENE-HBV interimyear-end 2026PBGENE-HBV interim, year-end 2026, material
- PBGENE-DMD interimyear-end 2026PBGENE-DMD interim, year-end 2026, material
- bepirovirsen GSK FDA decisionOct 26, 2026bepirovirsen GSK FDA decision, Oct 26, 2026, material
- DTIL 2024 Term Loan corporateJun 30, 2027DTIL 2024 Term Loan corporate, Jun 30, 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (5 active programs)
PBGENE-DMD
Gene Therapy Target: dystrophin gene, dystrophin
PBGENE-3243
Gene Therapy Target: mitochondrial DNA
ECUR-506
Gene Therapy Target: OTC gene
azer-cel
Technology platforms
ARCUS
ARCUS is a single-component genome editing platform based on engineered meganucleases. It enables gene insertion, elimination, and excision via staggered DNA cuts. Compatible with AAV and LNP delivery; small size allows inclusion of insertion DNA template in a single AAV. Applicable to genetic diseases, infectious diseases, and immunotherapy.
Discontinued (1)
- azercabtagene zapreleucel — Diffuse Large B-Cell Lymphoma
Biotech Distilled coverage (3)
- 2026-08-24 UPDATE: Precision BioSciences (DTIL) - The Needle Went In 🔒 Paid
- 2026-08-07 UPDATE: Precision BioSciences (DTIL) - The Loan Nobody Noticed 🔒 Paid
- 2026-07-17 Precision BioSciences (DTIL) — Scientific Deep Dive for PBGENE-HBV, PBGENE-DMD and the ARCUS Pipeline 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.